SpyGlass Pharma director reports initial share holdings

SpyGlass Pharma director Khan Bilal Arshad filed an initial ownership report showing his equity position in the company.

Rhea-AI Filing Summary

SpyGlass Pharma director Khan Bilal Arshad filed an initial ownership report showing his equity position in the company. He reports direct ownership of 5,450 shares of common stock and indirect beneficial ownership of 136,427 shares held by New World Medical, Inc., where he serves as Chief Executive Officer with voting and investment control.

He also holds stock options to purchase 11,992 shares of common stock at $2.18 per share and 48,533 shares at $7.11 per share. These options vest over time, subject to his continued service, with vesting schedules starting from September 20, 2023 and August 6, 2025.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Khan Bilal Arshad

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 60,525 contracts (Direct); Common Stock — 5,450 shares (Direct); Common Stock — 136,427 shares (Indirect, See footnote)

Footnotes (4)

1. F1. Shares held by New World Medical, Inc. (New World Medical). The Reporting Person is the Chief Executive Officer of New World Medical and as such has voting and investment control over the shares held by New World Medical.
2. F2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean September 20, 2023.
3. F3. Of the 100,000 shares subject to the option that were originally granted prior to a 5.7329 to 1 reverse stock split, 31,250 shares were exercised pre-reverse stock split and prior to the Reporting Person becoming a Section 16 director.
4. F4. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean August 6, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing show for SpyGlass Pharma (SGP)?

The Form 3 shows the initial equity holdings of director Khan Bilal Arshad in SpyGlass Pharma. It lists his direct and indirect common stock ownership, as well as stock options with specified share amounts, exercise prices, and service-based vesting schedules tied to defined vesting commencement dates.

How many SpyGlass Pharma (SGP) shares does Khan Bilal Arshad directly own?

Khan Bilal Arshad directly owns 5,450 shares of SpyGlass Pharma common stock. This direct ownership is reported in Table I of the filing as beneficially owned on a direct basis, separate from additional shares held indirectly through New World Medical, Inc.

What indirect SpyGlass Pharma (SGP) ownership is reported through New World Medical?

The filing reports 136,427 SpyGlass Pharma common shares held indirectly through New World Medical, Inc. Arshad is Chief Executive Officer of New World Medical and has voting and investment control over these shares, so they are reported as his indirect beneficial ownership.

What stock options in SpyGlass Pharma (SGP) does Khan Bilal Arshad hold?

Arshad holds two stock option grants to buy SpyGlass Pharma common shares. One covers 11,992 shares at an exercise price of $2.18 expiring September 19, 2033, and another covers 48,533 shares at $7.11 expiring August 5, 2035, both subject to vesting conditions.

How do the SpyGlass Pharma (SGP) stock options for Arshad vest?

Both option grants vest based on continued service as a Service Provider. For each grant, 25% vests on the one-year anniversary of its Vesting Commencement Date, with the remaining shares vesting monthly in equal installments over thirty-six months thereafter.

What are the vesting commencement dates for Arshad’s SpyGlass Pharma (SGP) options?

The first option grant uses a vesting commencement date of September 20, 2023. The second option grant uses a vesting commencement date of August 6, 2025. Each grant’s vesting schedule is calculated from its respective vesting commencement date, subject to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 01:06 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Khan Bilal Arshad

(Last) (First) (Middle)

C/O SPYGLASS PHARMA, INC.

27061 ALISO CREEK RD., SUITE 100

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/05/2026

3. Issuer Name and Ticker or Trading Symbol
SpyGlass Pharma, Inc. [ SGP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,450	D
Common Stock	136,427	I	See footnote(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(2)	09/19/2033	Common Stock	11,992(3)	$2.18	D
Stock Option (right to buy)	(4)	08/05/2035	Common Stock	48,533	$7.11	D

Explanation of Responses:

1. Shares held by New World Medical, Inc. (New World Medical). The Reporting Person is the Chief Executive Officer of New World Medical and as such has voting and investment control over the shares held by New World Medical.

2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean September 20, 2023.

3. Of the 100,000 shares subject to the option that were originally granted prior to a 5.7329 to 1 reverse stock split, 31,250 shares were exercised pre-reverse stock split and prior to the Reporting Person becoming a Section 16 director.

4. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean August 6, 2025.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Brian Aukshunas, as Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.